OJGas  Vol.5 No.12 , December 2015
Validity of Upper Gastro-Intestinal Endoscopic Screening in HCV Cirrhotic Patients Awaiting Antiviral Therapy
ABSTRACT
Background and Aim: The Egyptian Ministry of Health initiated a nationwide HCV treatment program with the newly developed oral antiviral therapies and formulated national guidelines for treatment allocation which gave favor for patients with advanced fibrosis and early cirrhosis. One of the recommendations for treatment was upper Gastro-intestinal (GIT) endoscopy. This study aimed at estimating the prevalence of varices among those patients and judging the validity of this national recommendation. Methods: This study was carried out at gastrointestinal endoscopy units, Zagazig University Hospitals through the year 2014. The epidemiologic, clinical features and endoscopic findings of patients undergoing preparation for HCV therapy were analyzed. Endoscopic classifications of esophageal and gastric varices were carried out after the Italian liver cirrhosis project and Sarin’s classification respectively. Results: Totally 1143 patients performed upper GIT endoscopy as preparation for HCV treatment. This comprised 22% of all patients undergoing upper GIT endoscopy over that year. There was a fourfold rise in percentage of patients undergoing endoscopy for sofosbuvir-based therapy in this year (22%) when compared to assessment for Interferon/Ribavirin combination therapy (5%) in the previous year. A total of 361 patients had no esophageal or gastric varices. Small sized (grade I), medium sized (grade II) and large sized (grade III) varices were reported in 301, 188 and 293 patients respectively. Thirty patients (2.6%) had gastric varices. The prevalence of varices was higher in Child B in comparison to Child A (statistically not significant, p = 0.243). Conclusion: Screening endoscopy for early cirrhotic patients awaiting oral anti-HCV therapy is valid.

Cite this paper
Mohamed, S. , Gaballah, B. and Emara, M. (2015) Validity of Upper Gastro-Intestinal Endoscopic Screening in HCV Cirrhotic Patients Awaiting Antiviral Therapy. Open Journal of Gastroenterology, 5, 191-199. doi: 10.4236/ojgas.2015.512029.
References
[1]   El-Zanaty, F. and Way, A. (2009) Egypt Demographic and Health Survey. Ministry of Health and Population, Cai-ro.

[2]   Farci, P., Alter, H.J., Wong, D., Miller, R.H., Shih, J.W., Jett, B., et al. (1991) A Long-Term Study of Hepatitis C Virus Replication in Non-A, Non-B Hepatitis. New England Journal of Medicine, 325, 98-104.
http://dx.doi.org/10.1056/NEJM199107113250205

[3]   Poza Cordon, J., Froilan Torres, C., Burgos García, A., Gea Rodriguez, F. and Suárez de Parga, J.M. (2012) Endoscopic Management of Esophageal Varices. World Journal of Gastro-intestinal Endoscopy, 4, 312-322.
http://dx.doi.org/10.4253/wjge.v4.i7.312

[4]   Italian Liver Cirrhosis Project (1987) Reliability of Endoscopy in the Assessment of Variceal Features. Journal of Hepatology, 4, 93-98.
http://dx.doi.org/10.1016/S0168-8278(87)80015-6

[5]   Berzigotti, A., Gilabert, R., Abraldes, J.G., Nicolau, C., Bru, C., Bosch, J., et al. (2008) Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients with Compensated Liver Cirrhosis. American Journal of Gastroenterology, 103, 1159-1167.
http://dx.doi.org/10.1111/j.1572-0241.2008.01826.x

[6]   Berzigotti, A., Seijo, S., Arena, U., Abraldes, J.G., Vizzutti, F., García-Pagán, J.C., et al. (2013) Elastography, Spleen Size, and Platelet Count Identify Portal Hypertension in Patients with Compensated Cirrhosis. Gastroenterology, 144, 102-111.
http://dx.doi.org/10.1053/j.gastro.2012.10.001

[7]   Sarin, S.K., Lahoti, D., Saxena, S.P., Murthy, N.S. and Makwana, U.K. (1992) Prevalence, Classification and Natural History of Gastric Varices: A Long-Term Follow-Up Study in 568 Portal Hypertension Patients. Hepatology, 16, 1343-1349.
http://dx.doi.org/10.1002/hep.1840160607

[8]   Doss, W., Mohamed, M.K., Esmat, G., El Sayed, M., Fontanet, A., Cooper, S., et al. (2008) Egyptian National Control Strategy for Viral Hepatitis 2008-2012. Arab Republic of Egypt, Ministry of Health and Population, National Committee for the Control of Viral Hepatitis.
http://www.hepnile.org/images/stories/doc/NSP_10_April_2008_final2.pdf

[9]   Afdhal, N.H., Zeuzem, S., Schooley, R.T., Thomas, D.L., Ward, J.W., Litwin, A.H., et al. (2013) The New Paradigm of Hepatitis C Therapy: Integration of Oral Therapies into Best Practices. Journal of Viral Hepatitis, 20, 745-760.
http://dx.doi.org/10.1111/jvh.12173

[10]   Doss, W. National Committee for the Control of Viral Hepatitis: Hope for Eradication.
http://www.liver-eg.org/assets/wahid-national-committee-for-control-treatment.pdf

[11]   Estes, C., Abdel-Kareem, M., Abdel-Razek, W., Abdel-Sameea, E., Abuzeid, M., Gomaa, A., et al. (2015) Economic Burden of Hepatitis C in Egypt: The Future Impact of Highly Effective Therapies. Alimentary Pharmacology & Therapeutics, 42, 696-706.
http://dx.doi.org/10.1111/apt.13316

[12]   Waked, I., Doss, W., El-Sayed, M.H., Estes, C., Razavi, H., Shiha, G., et al. (2014) The Current and Future Disease Burden of Chronic Hepatitis C Virus Infection in Egypt. Arab Journal of Gastroenterology, 15, 45-52.
http://dx.doi.org/10.1016/j.ajg.2014.04.003

[13]   Emam, M., Radwan, M., Refaey, M., Shaheen, N., Abd-ElMoez, S. and Gerges, M. (2015) Prevalence of Hepatitis C Virus in an Elderly Population in Rural Areas of Sharkia Governorate, Egypt. Egyptian Liver Journal, 5, 29-33.
http://dx.doi.org/10.1097/01.ELX.0000463678.53334.c7

[14]   Hepatitis, C. (2007) WHO Fact Sheet No. 164. 45-52.
http://www.who.int/mediacentre/factsheets/fs164/en/

[15]   Borgia, S.M. and Rowaiye, A. (2015) Increased Eligibility for Treatment of Chronic Hepatitis C Infection with Shortened Duration of Therapy: Implications for Access to Care and Elimination Strategies in Canada. Canadian Journal of Gastroenterology & Hepatology, 29, 125-129.

[16]   Hayes, C.N. and Chayama, K. (2015) Emerging Treatments for Chronic Hepatitis C. Journal of the Formosan Medical Association, 114, 204-215.
http://dx.doi.org/10.1016/j.jfma.2014.09.001

[17]   European Association for the Study of the Liver (2015) EASL Recommendations on Treatment of Hepatitis C 2015. Journal of Hepatology, 63, 199-236.
http://dx.doi.org/10.1016/j.jhep.2015.03.025

[18]   Elwakil, R., Reda, M.A., Abdelhakam, S.M., Ghoraba, D.M. and Ibrahim, W.A. (2011) Causes and Outcome of Upper Gastrointestinal Bleeding in Emergency Endoscopy Unit of Ain Shams University Hospital. Journal of the Egyptian Society of Parasitology, 41, 455-467.

[19]   Abdel-Wahab, M., el-Ebidy, G., Gad el-Hak, N., Abou-Elenin, A., Abou-Zid, M., el-Ghawalby, N., et al. (1999) Fundal Varices: Problem and Management. Hepato-Gastroenterology, 46, 849-854.

[20]   Garcia-Tsao, G., Sanyal, A.J., Grace, N.D., Carey, W., Practice Guidelines Committee of the American Association for the Study of Liver Diseases, Practice Parameters Committee of the American College of Gastroenterology (2007) AASLD Practice Guidelines: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis. Hepatology, 46, 922-938.

[21]   El Naggar, A.A., Gomaa, M.S. and Fawzy, M.M. (2012) Nonendoscopic Predictors of Large Esophageal Varices. The Egyptian Journal of Internal Medicine, 24, 97-99.

[22]   Hussein, H.A., Tamer, W.M. and Khalaf, M.S. (2015) AST/ALT Ratio for Detection and Severity Classification of Esophageal Varices in Child A HCV Liver Cirrhosis in Egyptian Patients. Life Science Journal, 12, 12-17.

[23]   Abdelaziz, A. and Yousif, M. (2014) Prevalence and Outcome of Bleeding Gastro-Esophageal Varices in Medical Intensive Care Unit at Zagazig University Hospitals, Egypt. Afro-Egyptian Journal of Infectious and Endemic Diseases, 4, 13-22.

[24]   Mandorfer, M., Kozbial, K., Freissmuth, C., Schwabl, P., St€attermayer, A.F., Reiberger, T., et al. (2015) Interferon-Free Regimens for Chronic Hepatitis C Overcome the Effects of Portal Hypertension on Virological Responses. Alimentary Pharmacology & Therapeutics, 42, 707-718.
http://dx.doi.org/10.1111/apt.13315

 
 
Top